A phase 2 evaluation of irofulven as second-line treatment of recurrent or persistent intermediately platinum-sensitive ovarian or primary peritoneal cancer: A gynecologic oncology group trial

Russell J. Schilder, John A. Blessing, Mark S. Shahin, David S. Miller, Krishnansu Sujata Tewari, Carolyn Y. Muller, David P. Warshal, Scott McMeekin, Jacob Rotmensch

Research output: Contribution to journalArticlepeer-review

14 Scopus citations
Original languageEnglish (US)
Pages (from-to)1137-1141
Number of pages5
JournalInternational Journal of Gynecological Cancer
Issue number7
StatePublished - Oct 2010


  • GOG
  • Irofulven
  • Platinum-sensitive ovarian cancer
  • Primary peritoneal cancer

ASJC Scopus subject areas

  • Oncology
  • Obstetrics and Gynecology

Cite this